Centro Hospitalar de Lisboa Ocidental, Hospital Egas Moniz , Lisboa , Portugal.
Curr Med Res Opin. 2014 Jan;30(1):89-97. doi: 10.1185/03007995.2013.844685. Epub 2013 Oct 4.
Review of the available data on the currently available single-tablet regimens (STRs), from the analysis of efficacy and safety to the key points of value in terms of adherence, quality of life and pharmacoeconomic evaluation.
For this narrative review, literature searches have been performed in PubMed, IndexRevMed and Cochrane, using the search terms HIV, single-tablet, one-pill, single dose, fixed-dose, and STR. These have been reviewed and complemented with the most recent publications of interest.
Fixed-dose combinations are a significant advance in antiretroviral treatment simplification, contributing to an increase in compliance with complex chronic therapies, thus improving patients' quality of life. Reducing the number of pills and daily doses is associated with higher adherence and better quality of life. As a fixed-dose combination tablet given once daily, EFV/FTC/TDF was the first available STR combining efficacy, tolerability and convenience, with the simplest dosing schedule and smallest numbers of pills of any ART combination therapy. The RPV/FTC/TDF is a next-generation NNRTI-based STR, a once daily complete ART regimen for the treatment of HIV-1 infection. Recently the combination of EVG/COBI/FTC/TDF was also approved by the European Commission, and is the first integrase inhibitor-based STR. Receiving antiretroviral therapy as once daily STR is associated with both clinical and economic benefits, which confirms previous research.
The associated benefits of STRs provide a valid strategy for the treatment of HIV-infected patients.
从疗效和安全性分析到依从性、生活质量和药物经济学评价方面的价值要点，对现有单一片剂方案（STR）的现有数据进行综述。
本文为叙述性综述，在 PubMed、IndexRevMed 和 Cochrane 中使用了 HIV、单一片剂、一丸、单剂量、固定剂量和 STR 等搜索词进行文献检索，对这些搜索词进行了回顾，并补充了最新的相关出版物。
固定剂量组合是抗逆转录病毒治疗简化的重大进展，有助于提高复杂慢性治疗的依从性，从而提高患者的生活质量。减少药丸数量和每日剂量与更高的依从性和更好的生活质量相关。EFV/FTC/TDF 作为每日一次的固定剂量组合片剂，是第一种可用的 STR，它结合了疗效、耐受性和便利性，具有任何 ART 联合治疗方案中最简单的给药方案和最小的药丸数量。RPV/FTC/TDF 是一种基于下一代 NNRTI 的 STR，是一种每日一次的完整 ART 方案，用于治疗 HIV-1 感染。最近，EVG/COBI/FTC/TDF 的联合也获得了欧洲委员会的批准，这是第一个基于整合酶抑制剂的 STR。接受每日一次 STR 的抗逆转录病毒治疗与临床和经济效益相关，这证实了之前的研究。
STR 的相关益处为治疗 HIV 感染患者提供了有效的策略。
